文献速递妇科

子宫内膜癌分子分型与首次复发时间、复发模式及复发后生存的关系

Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification.
PubMed 文献 · Gynecol Oncol · 2022-03-08

本研究纳入瑞典Karolinska大学医院和瑞士Bern大学医院2004至2015年原发手术且行分子分型的复发性子宫内膜癌患者(KImBer队列),594例中101例复发。中位首次复发时间16个月(95%CI 12-20),MMRd最短13个月(95%CI 5-21);复发模式在分子亚组间不同(P=.042);复发后中位生存MMRd 43个月(95%CI 11-76)、NSMP 39个月(95%CI 21-57)、p53abn 10个月(95%CI 7-13)(log-rank P=.001)。

要点

  • 复发后中位生存:MMRd 43个月,NSMP 39个月,p53abn 10个月(log-rank P=.001)。
  • 中位首次复发时间总体16个月(95%CI 12-20),MMRd最短13个月(95%CI 5-21)。
  • MMRd更多局部区域复发,p53abn更多腹部复发(P=.042)。

核心结论

  • 分子分型是子宫内膜癌患者复发后生存的显著指标,且复发模式因分子亚组而异。
  • MMRd子宫内膜癌更多局部区域复发且复发后生存率最佳,p53abn患者更常腹部复发且在所有复发患者中预后最差。

研究设计与样本

  • 纳入2004至2015年在瑞典Karolinska大学医院和瑞士Bern大学医院接受原发手术治疗且原发肿瘤行分子分型的复发性子宫内膜癌患者(KImBer队列)。
  • 594例分子分型子宫内膜癌患者中101例复发,包括POLEmut 2例、MMRd 33例、p53abn 30例、NSMP 36例。
  • 复发时平均年龄71岁,平均随访54个月。

主要发现

  • 总体中位首次复发时间为16个月(95%CI 12-20),MMRd患者最短为13个月(95%CI 5-21)。
  • 复发模式在分子亚组间不同:MMRd肿瘤更多局部区域复发,p53abn病例更多腹部复发(P=.042)。
  • 复发后中位生存MMRd为43个月(95%CI 11-76),NSMP为39个月(95%CI 21-57),p53abn为10个月(95%CI 7-13)(log-rank P=.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Despite its generally favorable prognosis at primary diagnosis, recurrence of endometrial cancer remains an important clinical challenge. The aim of this study was to analyze the value of molecular classification in recurrent endometrial cancer. METHODS: This study included patients with recurrent endometrial cancer who underwent primary surgical treatment between 2004 and 2015 at the Karolinska University Hospital, Sweden and the Bern University Hospital, Switzerland (KImBer cohort) with molecular classification of the primary tumor. RESULTS: Out of 594 molecularly classified endometrial cancer patients, 101 patients experienced recurrence, consisting of 2 POLEmut, 33 MMRd, 30 p53abn, and 36 NSMP tumors. Mean age at recurrence was 71 years and mean follow-up was 54 months. Overall, median time to first recurrence was 16 months (95% CI 12-20); with the shortest median time in MMRd patients, with 13 months (95% CI 5-21). The pattern of recurrence was distinct among molecular subgroups: MMRd tumors experienced more locoregional, while p53abn cases showed more abdominal recurrences (P = .042). Median survival after recurrence was best for MMRd cases (43 months, 95% CI 11-76), compared to 39 months (95% CI 21-57) and 10 months (95% CI 7-13) for the NSMP and p53abn cases respectively (log-rank, P = .001). CONCLUSION: Molecular classification is a significant indicator of survival after recurrence in endometrial cancer patients, and patterns of recurrence differ by molecular subgroups. While MMRd endometrial cancer show more locoregional recurrence and the best survival rates after recurrence, p53abn patients experience abdominal recurrence more often and had the worst prognosis of all recurrent patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Siegenthaler F, Lindemann K, Epstein E, et al. Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification. Gynecol Oncol. 2022. PMID: 35277281. doi:10.1016/j.ygyno.2022.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。